Ultragenyx Pharmaceutical (RARE) Institutional Ownership

97.67% of Ultragenyx Pharmaceutical's stock is owned by institutional investors. Learn more on RARE's institutional investor holdings.

Of the 294 institutional investors that purchased Ultragenyx Pharmaceutical's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BlackRock Inc. ($10.65M), Norges Bank ($3.21M), Assenagon Asset Management S.A. ($3.16M), Eagle Health Investments LP ($1.90M), Jacobs Levy Equity Management Inc. ($1.86M), Vestal Point Capital LP ($1.50M), and Jefferies Financial Group Inc. ($1.41M).

Institutional investors have bought a total of 41,606,718 shares in the last 24 months. This purchase volume represents approximately $1.19B in transactions.

Of the 83 institutional investors that sold Ultragenyx Pharmaceutical's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Assenagon Asset Management S.A. ($3.10M), Federated Hermes Inc. ($1.55M), Wellington Management Group LLP ($1.39M), Alliancebernstein L.P. ($1.23M), Deutsche Bank AG ($946.63K), Alyeska Investment Group L.P. ($897.44K), and Farallon Capital Management LLC ($891K).

Institutional investors have sold a total of 18,536,917 shares in the last 24 months. This volume of shares sold represents approximately $521.00M in transactions.